NeuroScientific Biopharmaceuticals Ltd. announced the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB, achieving a significant milestone in the development of EmtinB as a first-in-class treatment with disease modifying potential for neurodegenerative conditions, such as Multiple sclerosis and Alzheimer's disease. The early-phase clinical trial is being undertaken by leading WA-based clinical research partner Linear Clinical Research.